Performance and carcass characteristics of lambs fed diets with fat and vitamin E

Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais (FAPEMIG)Empresa de Pesquisa Agropecu?ria de Minas Gerais (EPAMIG)Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (CNPq)Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior (CAPES)This experiment aimed to determine the influence of diets with inclusion of protected fat and vitamin E on performance, yield and carcass characteristics of feedlot lambs with different weights. Thirty-two non-castrated Santa Ines lambs were fed diets with a ratio of 40% forage and 60% concentrate ad libitum, with presence or absence of protected fat and/or vitamin E, in a total of four diets. Two weights of early containment were also considered: between 20 and 25 kg and between 30 and 35 kg. All animals were slaughtered at 84 days of confinement. Animals fed diets without addition of protected fat, regardless of the use of vitamin E, had the highest intakes of dry matter, crude protein, neutral detergent fiber and ash, and decreased intake of ether extract. The variables investigated did not affect daily weight gain and total gain. Feed conversion was better for the lighter confined animals not fed protected fat. The heavier feedlot lambs fed diets with vitamin E showed higher cold carcass. The warm carcass for the lighter animals confined fed with vitamin E, and the heavier ones, fed with protected fat and vitamin E, showed the best yields of cold carcass. Objective measures of the carcass cold had the highest mean for heavier feedlot lambs. The addition of fat in the diet reduces the intake of dry matter and increases the ether extract. Although the inclusion of vitamin has no effect on intake of nutrients, it protects the carcasses from losses during cooling, and weight differences at containment directly reflect the measures of the carcasses

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Background: Patients with inflammatory bowel disease who achieve remission with anti-tumour necrosis factor (anti-TNF) drugs may have treatment withdrawn due to safety concerns and cost considerations, but there is a lack of prospective, controlled data investigating this strategy. The primary study aim is to compare the rates of clinical remission at 1?year in patients who discontinue anti-TNF treatment versus those who continue treatment. Methods: This is an ongoing, prospective, double-blind, multicentre, randomized, placebo-controlled study in patients with Crohn?s disease or ulcerative colitis who have achieved clinical remission for ?6?months with an anti-TNF treatment and an immunosuppressant. Patients are being randomized 1:1 to discontinue anti-TNF therapy or continue therapy. Randomization stratifies patients by the type of inflammatory bowel disease and drug (infliximab versus adalimumab) at study inclusion. The primary endpoint of the study is sustained clinical remission at 1?year. Other endpoints include endoscopic and radiological activity, patient-reported outcomes (quality of life, work productivity), safety and predictive factors for relapse. The required sample size is 194 patients. In addition to the main analysis (discontinuation versus continuation), subanalyses will include stratification by type of inflammatory bowel disease, phenotype and previous treatment. Biological samples will be obtained to identify factors predictive of relapse after treatment withdrawal. Results: Enrolment began in 2016, and the study is expected to end in 2020. Conclusions: This study will contribute prospective, controlled data on outcomes and predictors of relapse in patients with inflammatory bowel disease after withdrawal of anti-TNF agents following achievement of clinical remission. Clinical trial reference number: EudraCT 2015-001410-1